Entera Bio's Lead Osteoporosis Drug EB613 Data Selected for Late-Breaking Oral Presentation at ENDO 2026
ENTX sits 37% above its 52-week low of $0.91.
Summary
Entera Bio's lead osteoporosis drug candidate, EB613, has been selected for a prestigious late-breaking oral presentation at the upcoming ENDO 2026 annual meeting. This positive development highlights new clinical data for the first-in-class oral PTH(1-34) anabolic, following the company's recent submission of a streamlined Phase 3 protocol to the FDA. For a clinical-stage biotech, this validation of its most advanced asset is crucial, especially after recent financial activities to extend its cash runway. Investors will be watching for the full data presentation at ENDO 2026, taking place June 13-16.
At the time of this announcement, ENTX was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.6M. The 52-week trading range was $0.91 to $3.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.